Filtered By:
Specialty: Cardiology
Drug: Angiomax

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions: Observational, Propensity-Matched Analysis From the Premier Hospital Database Peripheral Vascular Disease
Conclusions— In patients undergoing peripheral vascular interventions, procedural anticoagulation with bivalirudin may result in more favorable in-hospital outcomes compared with unfractionated heparin, the current standard of care. These observations will require prospective confirmation in a randomized, controlled trial.
Source: Circulation: Cardiovascular Interventions - January 8, 2016 Category: Cardiology Authors: Kimmelstiel, C., Pinto, D., Aronow, H. D., Weintraub, A. R., Dangas, G., Fan, W., Prats, J., Deliargyris, E. N., Katzen, B. T. Tags: Anticoagulants, Pharmacology, Peripheral Vascular Disease, Vascular Disease Source Type: research

Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement The Randomized BRAVO-3 Trial
BackgroundAnticoagulation is required during transcatheter aortic valve replacement (TAVR) procedures. Although an optimal regimen has not been determined, heparin is mainly used. Direct thrombin inhibition with bivalirudin may be an effective alternative to heparin as the procedural anticoagulant agent in this setting.ObjectivesThe goal of this study was to determine whether bivalirudin offers an alternative to heparin as the procedural anticoagulant agent in patients undergoing TAVR.MethodsA total of 802 patients with aortic stenosis were randomized to undergo transfemoral TAVR with bivalirudin versus unfractionated hepa...
Source: Journal of the American College of Cardiology - December 21, 2015 Category: Cardiology Source Type: research

TCT: Structural Heart Disease and PFO Closure TrialsTCT: Structural Heart Disease and PFO Closure Trials
Drs Harrington and Bhatt discuss whether transcatheter aortic valve therapy is evolving naturally or moving beyond the evidence, bivalirudin in TAVR, and PFO closure for stroke prevention. theheart.org on Medscape
Source: theHeart.org - October 19, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention: Prespecified Subgroup Analysis From the EUROMAX Trial Coronary Interventions
Conclusions— In this prespecified analysis from EUROMAX, radial access was preferred in lower risk patients and did not improve clinical outcomes. Bivalirudin was associated with less bleeding irrespective of access site. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01087723.
Source: Circulation: Cardiovascular Interventions - June 8, 2015 Category: Cardiology Authors: Hamon, M., Coste, P., van't Hof, A., Ten Berg, J., Clemmensen, P., Tabone, X., Benamer, H., Kristensen, S. D., Cavallini, C., Marzocchi, A., Hamm, C., Kanic, V., Bernstein, D., Anthopoulos, P., Deliargyris, E. N., Steg, P. G. Tags: Cardiovascular Pharmacology, Catheter-based coronary and valvular interventions: other, Acute myocardial infarction Coronary Interventions Source Type: research

Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials
BackgroundIn the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) treated with bivalirudin had lower bleeding and mortality rates, but higher acute stent thrombosis rates compared with heparin + a glycoprotein IIb/IIIa inhibitor (GPI). Subsequent changes in primary PCI, including the use of potent P2Y12 inhibitors, frequent radial intervention, and pre-hospital medication administration, were incorporated into the EUROMAX (European Ambu...
Source: Journal of the American College of Cardiology - January 5, 2015 Category: Cardiology Source Type: research

A regional pharmacoinvasive PCI strategy incorporating selected bleeding avoidance strategies
ConclusionBleeding and ischemia rates were similar between the PIT and primary PCI strategies in the setting of routine use of selected BAS; further study on a broader range of BAS including the radial approach may be warranted. Cardiac arrest and bailout glycoprotein IIb/IIIa inhibitor, but not PIT in conjunction with selected BAS, are independent predictors of bleeding risk in a regional ST-segment elevation myocardial infarction population.
Source: Coronary Artery Disease - December 10, 2014 Category: Cardiology Tags: Original Research Source Type: research

Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Marco Valgimigli Background Transradial intervention (TRI) and bivalirudin infusion compared with transfemoral coronary intervention or unfractionated heparin plus glycoprotein IIb/IIIa inhibitors decrease bleeding complications in patients with acute coronary syndromes (ACS). Although bleeding is thought to be associated with worse outcomes, it remains unclear whether TRI and bivalirudin both independently lower ischemic or combined ischemic and bleeding complications in ACS patients undergoing contemporary invasive management....
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research

Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial. Clinical trial registration information Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research

Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry.
Conclusions: Bivalirudin usage in the setting of primary PCI provided excellent results in terms of 30-day outcome even in a real-world population. PMID: 25101656 [PubMed - as supplied by publisher]
Source: Acute Cardiac Care - August 7, 2014 Category: Cardiology Authors: Limbruno U, Picchi A, Galli S, Huber K, Lipiecki J, Bernstein D, Deliargyris E, Anthopoulos P, Nienaber C, Hamon M Tags: Acute Card Care Source Type: research

Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
Conclusion: In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.
Source: International Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Martial Hamon, Christopher A. Nienaber, Stefano Galli, Kurt Huber, Janusz Lipiecki, Jonathan M. Hill, Nicolas Amabile, Debra Bernstein, Efthymios Deliargyris, Antoine Lafont, Philippe Gabriel Steg Tags: Original Articles Source Type: research

Bivalirudin use and one‐month outcome in the context of contemporary antiplatelet treatment: Insights from the Greek Antiplatelet Registry
ConclusionsIn a ‘real life’, contemporary antiplatelet treatment registry, clinical, laboratory and logistic factors affect bivalirudin's choice, while there are no differences in one‐month outcome between bivalirudin and no bivalirudin treated patients.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - February 1, 2014 Category: Cardiology Authors: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Spyridon Deftereos, George Sitafidis, Ioannis Kanakakis, Michalis Hamilos, George Karayannis, Christos Angelidis, Katerina Stavrou, Manolis Vavuranakis, John A. Goudevenos, Christodoulos Stefanadis, Tags: Original Research Article Source Type: research

Association Between Intraprocedural Thrombotic Events and Adverse Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction HORIZONS-AMI Substudy)
The present study sought to determine the extent to which adverse angiographic events encountered during percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) are associated with adverse clinical outcomes. Patients with STEMI represent a cohort at particularly high risk of intraprocedural thrombotic events (IPTEs). The overall frequency and implications of IPTEs occurring in patients with STEMI have not been systematically quantified in previous studies. A total of 3,163 patients undergoing primary percutaneous coronary intervention with stent implantation for STEMI in the Harmonizing Ou...
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Ajay J. Kirtane, Prabhdeep Sandhu, Roxana Mehran, Margaret McEntegart, Ecaterina Cristea, Sorin J. Brener, Ke Xu, Martin Fahy, Philippe Généreux, Jeffrey D. Wessler, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
In conclusion, in patients with STEMI who underwent primary PCI of LAD, the use of bivalirudin was associated with a reduction in mortality and bleeding rates at 3 years. PES reduced revascularization rates in this population but did not have a significant impact on mortality.
Source: The American Journal of Cardiology - June 10, 2013 Category: Cardiology Authors: Jochen Wöhrle, Bruce Brodie, Bernhard Witzenbichler, Dariusz Dudek, Ran Kornowski, Chris Metzger, Cindy Grines, Thomas C. McAndrew, Helen Parise, Ziad Sergie, Roxana Mehran, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research

Hemorrhagic and Ischemic Outcomes After Bivalirudin Versus Unfractionated Heparin During Carotid Artery Stenting: A Propensity Score Analysis From the NCDR Peripheral Vascular Disease
Conclusions— Bivalirudin was associated with lower rates of hemorrhagic outcomes compared with UFH during the index hospitalization for carotid artery stenting. In-hospital and 30-day ischemic events were similar between the 2 groups. Randomized comparisons of these agents are needed to confirm these findings.
Source: Circulation: Cardiovascular Interventions - April 16, 2013 Category: Cardiology Authors: Wayangankar, S. A., Abu-Fadel, M. S., Aronow, H. D., Kennedy, K. F., Gupta, R., Yeh, R. W., Gray, W. A., Rosenfield, K., Hennebry, T. A. Tags: Heparin, Other anticoagulants, Carotid Stenosis, Angioplasty and Stenting, Transient Ischemic Attacks Peripheral Vascular Disease Source Type: research